Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells

Chen, Yili; Tang, Jun‐Ming; Chen, Peisong; Ouyang, Jian; Xu, Gaixia; Zeng, Zhijie; Sun, Yanhong

doi:10.1016/j.psychres.2010.10.029

Cited by 155 publications

(110 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data are in accordance with previous studies indicating a relative deficiency of CD4 + T helper cells in patients with MDD (Chen et al 2011;Szuster-Ciesielska et al 2008). CD4 + CD25 high Foxp3 + T regulatory cells help to maintain tolerance to self-antigens, dampen monocyte activation, and dampen T h 1, T h 2, and T h 17 cells.…”

Section: Discussionsupporting

confidence: 93%

Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Interestingly, elevated serum levels of IL-17A and decreased indexes of immunity in depressed animal models have been previously reported (27). These results were confirmed by Chen et al who revealed that the number of Th17 cells, and the ratio of Th17/T regulatory cells and serum levels of IL-17A, were significantly increased in depressed patients compared to healthy controls (18). Upregulation of IL-17A in an animal model of depression has also been reported by Kim et al (25).…”

Section: Il-17a and Depressionsupporting

confidence: 69%

“…IL-17A participates either in the immune response against infection (a beneficial effect) (16) or in the pathogenesis of autoimmunity and immune-related disorders (17). Although IL-17A participates in autoimmunity, there is limited data regarding its role in the pathogenesis of immune-related disease, including inflammatory conditions and depression (18). On the other hand, IL-17A activates innate immune cells, playing an important role in the pathogenesis of immune-related disease (19).…”

Section: Contextmentioning

confidence: 99%

The Role of Interleukin-17A (IL-17A) in Depression

Fathalizadeh

Mirzabeigi

et al. 2016

Iran Red Crescent Med J

View full text Add to dashboard Cite

Context: The aim of this review was to address the recent data regarding the role of IL-17A in the pathogenesis of depression and its complications, such as cancer. Evidence Acquisition: This review article summarizes the recent data on the role of IL-17A in depression, using the PubMed and Google Scholar databases. Results: It has been documented that depression may alter the immune response via unknown mechanism/s. It is possible that immune responses and depression are linked via several molecules, including cytokines. IL-17A, a pro-inflammatory cytokine, participates in the pathogenesis of several inflammatory-based diseases, such as autoimmunity. Conclusions: Due to the comorbidity of depression and chronic inflammatory processes, and depression's effect on the immune system, it may be hypothesized that the IL-17A cytokine plays a key role in the pathogenesis of depression.

show abstract

“…Moreover, decreases in counterregulatory immunologic functions including T regulatory cells (Tregs) and their production of the anti-inflammatory cytokines TGF-β and IL-10 have been described (Sutcigil et al, 2007;Li et al, 2010;Chen et al, 2011). Of note, depletion of Tregs leads to anxiety and depressive-like behavior in mice (Kim et al, 2012).…”

Section: Foundations For the Hypothesis That The Immune System Playsmentioning

confidence: 99%

Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation

Miller

Haroon

Felger

2016

Neuropsychopharmacol

118

124

View full text Add to dashboard Cite

A wealth of data has been amassed that details a complex, yet accessible, series of pathways by which the immune system, notably inflammation, can influence the brain and behavior. These data have opened the window to a diverse array of novel targets whose potential efficacy is tied to specific neurotransmitters and neurocircuits as well as specific behaviors. What is clear is that the impact of inflammation on the brain cuts across psychiatric disorders and engages dopaminergic and glutamatergic pathways that regulate motivation and motor activity as well as the sensitivity to threat. Given the ability to identify patient populations with increased inflammation, the precision of interventions can be further tuned, in conjunction with the ability to establish target engagement in the brain through the use of multiple neuroimaging strategies. After a brief overview of the mechanisms by which inflammation affects the brain and behavior, this review examines the extant literature on the efficacy of anti-inflammatory treatments, while forging guidelines for future intelligent clinical trial design. An examination of the most promising therapeutic strategies is also provided, along with some of the most exciting clinical trials that are currently being planned or underway.

show abstract

Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells

Cited by 155 publications

References 44 publications

Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy

Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy

The Role of Interleukin-17A (IL-17A) in Depression

Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation

Contact Info

Product

Resources

About